Comparison of purified psoralen-inactivated and formalin-inactivated dengue vaccines in mice and nonhuman primates
Open Access
- 1 April 2020
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 38 (17), 3313-3320
- https://doi.org/10.1016/j.vaccine.2020.03.008
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of Defense
This publication has 27 references indexed in Scilit:
- The global distribution and burden of dengueNature, 2013
- Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeysVaccine, 2011
- Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in MiceClinical and Vaccine Immunology, 2010
- A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue VirusJournal of Virology, 2008
- A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaquesVirology, 2006
- Fundamentals of the psoralen-based Helinx™ technology for inactivation of infectious pathogens and leukocytes in platelets and plasmaSeminars in Hematology, 2001
- Fundamentals of the psoralen-based Helinx[trade ] technology for inactivation of infectious pathogens and leukocytes in platelets and plasmaSeminars in Hematology, 2001
- A High Frequency of Sequence Alterations Is Due to Formalin Fixation of Archival SpecimensThe American Journal of Pathology, 1999
- Development of a Purified, Inactivated, Dengue-2 Virus Vaccine Prototype in Vero Cells: Immunogenicity and Protection in Mice and Rhesus MonkeysThe Journal of Infectious Diseases, 1996
- Photochemical Inactivation of DNA and RNA Viruses by Psoralen DerivativesJournal of General Virology, 1978